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progression of renal disease. Also, as we discuss in our
article, it could be the focus of therapeutic interventions
to slow progression of renal disease.
In light of the above, we suggest that the technical
concerns of Mr. Basgen and Dr. Mauer do not invalidate
the conclusions of our article. Nevertheless, their con-
cerns are highly appropriate. Indeed, we endorse their
proposal that scientific journals should adopt the high
standards proposed by Nyengaard for morphometric
studies. Our endorsement, however, is modified in two
respects. First, Nyengaard’s article is too technical. Inves-
tigators may be dissuaded from doing morphometric
studies if they will be judged by the principles contained
in his article. Second, we suggest that a much simpler,
applied version of Nyengaard’s principles should be pub-
lished. Dr. Mauer and his group would be ideal candi-
dates to execute such work. Dr. Mauer is a bellwether
investigator in this field and is noted for his lucid exposi-
tion of data.
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Different response of urinary
excretion of VEGF in patients
with chronic and acute renal
failure
To the Editor: Vascular endothelial growth factor
(VEGF) is constitutively expressed by epithelial cells of
a nephron from embryonic to adult kidneys. In renal
disease, VEGF appears to be involved in a repair of the
glomerulus [1]. It is excreted in urine [2] and is suspected
to be secreted from tubular cells by hypoxic stimulation
in vitro [3, 4] and in vivo [4]. Thus, because the amount
of urinary VEGF might reflect renal hypoxia, we mea-
sured it in patients with renal diseases and various renal
functions.
A total of 29 urine and 26 serum and plasma samples Fig. 1. Relationship of urinary excretion of vascular endothelial
growth factor (VEGF) with 24 hours’ creatinine clearance (CCr) andwere collected from 22 non-diabetic non-nephrotic pa-
serum level of VEGF. (A) VEGF excretion in urine per day vs.tients without serious complications. Fifteen patients had CCr in patients with chronic renal injury. VEGF excretion in urine
a renal biopsy (11 with IgA nephropathy, two with mem- inversely correlated with CCr (simple regression analysis: Y 5 117.2–
0.92X, P 5 0.0003 for the slope; R 5 0.620). (B) VEGF excretionbranous nephropathy, one with focal segmental glomeru-
in urine vs. VEGF level in serum in patients with chronic renal
injury. (C) VEGF excretion in urine per day vs. CCr in patients with
ischemic acute renal failure. The three symbols indicate individual
patients.
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losclerosis, and one with membranoproliferative glomer- Criteria for calcimimetic agent
ulonephritis). The other seven patients were clinically
diagnosed with chronic renal failure. Twelve urine and in the treatment of more
serum samples were collected from three patients with
ischemic acute renal failure. As VEGF concentration in severe secondary
the urine did not change after 24 hours’ incubation at
room temperature, those urine samples were stored at hyperparathyroidism
2308C until use and submitted to colorimetric enzyme
immunoassay to quantitate VEGF. Renal function was To the Editor: The prevention and treatment of sec-
ondary hyperparathyroidism still are challenging for theevaluated by 24-hour creatinine clearance (CCr).
There was an inverse relationship between urinary nephrologist. Therefore, the recent work of Goodman
et al is very interesting and promising [1]. The goal ofexcretion of VEGF and CCr (Fig. 1A). VEGF excretion
in urine did not correlate with its serum (Fig. 1B) or their study was to assess the safety and efficacy of a
calcimimetic agent in dialysis patients with modest toplasma level (data not shown). In patients with acute
renal failure, no correlation was observed between uri- severe secondary hyperparathyroidism. However, their
study appears to focus only on a single criterion fornary excretion of VEGF and CCr (Fig. 1C).
We examined patients with a wide range of renal func- modest or severe secondary hyperparathyroidism, the
level of intact parathyroid hormone (PTH). It is welltions to focus on the relationship between urinary VEGF
and renal function. In patients with chronic renal failure, known that secondary hyperparathyroidism is a state of
increased synthesis and secretion of PTH, but also a stateVEGF excretion in urine increased as renal function
of increased hypertrophy and particularly hyperplasia ofdecreased. Since excretion was independent of the serum
the parathyroid cells [2]. There are two forms of parathy-level of VEGF, urinary VEGF appears to be derived
roid gland hyperplasia, diffuse and nodular. Parathyroidfrom the kidney. Therefore, increased excretion of
glands with nodular hyperplasia are larger. In 90% ofVEGF suggests its increased secretion in residual neph-
parathyroid glands weighing 0.5 g nodular hyperplasiarons under diffuse and continuous hypoxia. In patients
was found. Such nodules are made of cells with signifi-with acute renal failure, urinary VEGF excretion was
cantly reduced numbers of vitamin D receptors, calcium-independent of renal function, probably because excre-
sensing receptors (CaSR), and a higher calcium set pointtion of VEGF from the kidney did not change much
for PTH secretion. From a clinical point of view, it issince the ischemic period was transient and the area was
important to note that patients with nodular parathyroidlimited. Although further studies are needed, urinary
gland hyperplasia are often resistant to calcitriol therapy.VEGF might be a unique indicator of renal hypoxia.
Today, high-resolution sonography is the best tech-
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lar hyperplasia have reduced numbers of CaSR, it would
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Despite these remarks, we hope that a new calcimi-
metic agent, as well as new phosphate binders and newREFERENCES
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